Company Overview - NeuroPace, Inc. is a medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy by reducing or eliminating debilitating seizures [3] - The company offers the RNS System, which is the first and only commercially available brain-responsive platform that delivers personalized, real-time treatment at the seizure source [3] - The RNS System aims to improve the standard of care for patients with drug-resistant epilepsy and has potential applications for other brain disorders [3] Upcoming Events - NeuroPace's management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, CA [1] - The presentation will be accessible via live webcast, with a replay available for two weeks following the event on NeuroPace's Investor website [2]

Core Insights - NeuroPace, Inc. will host an Investor Day on January 28, 2025, in New York City to discuss its vision for RNS technology and future plans [1][2] - The event will feature management presentations on recent results, market strategies, and clinical development for the RNS System, along with guest speakers including clinical experts and an RNS patient [2] Company Overview - NeuroPace is a medical device company based in Mountain View, California, focused on improving the lives of individuals with epilepsy by reducing or eliminating seizures [3] - The RNS System is the first commercially available brain-responsive platform that provides personalized, real-time treatment at the source of seizures, aiming to enhance care for patients with drug-resistant epilepsy [3]

Core Insights - NeuroPace, Inc. has completed enrollment and implant procedures in its feasibility investigational device exemption (IDE) study of the RNS® System for treating Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsy [1][4] - The IDE study aims to evaluate the safety and effectiveness of the RNS System, which has previously shown success in treating medically intractable focal onset seizures in adults [2][3] - The study is funded by a $9.3 million NIH grant and involves 20 patients aged 12 and older with LGS and drug-resistant generalized onset seizures [3] Company Overview - NeuroPace is a commercial-stage medical device company based in Mountain View, California, focused on transforming the lives of individuals with epilepsy through innovative treatments [6] - The RNS® System is the first and only FDA-approved brain-responsive neuromodulation system, designed to provide personalized, real-time treatment by continuously monitoring brain activity [5][6] - The system has demonstrated significant reductions in seizure frequency and improvements in quality of life and cognition without stimulation-related side effects [5] Industry Context - LGS is a debilitating seizure disorder with 85% of affected individuals continuing to experience seizures into adulthood despite aggressive treatment, highlighting the urgent need for innovative treatment options [4] - The RNS System's technology represents a paradigm shift in the treatment of drug-resistant epilepsy, potentially offering better outcomes for a large population suffering from various brain disorders [5][6]

NeuroPace, Inc. (NPCE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changin ...

Core Viewpoint - NeuroPace, Inc. (NPCE) shares have increased by 38.8% in the past four weeks, closing at $8.98, with a mean price target of $13.86 indicating a potential upside of 54.3% according to Wall Street analysts [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $4.14, where the lowest estimate suggests a 10.9% decline to $8, while the highest estimate predicts a 100.5% increase to $18 [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [7] Earnings Estimates and Analyst Sentiment - There is growing optimism among analysts about NPCE's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 7.6%, with four estimates moving higher and no negative revisions [10] Zacks Rank and Investment Potential - NPCE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [11] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a useful guide for the direction of price movement [12]

NeuroPace, Inc. (NASDAQ:NPCE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Mike Kratky – Leerink Partners Vik Chopra – Wells Fargo Ross Osborn – Cantor Fitzgerald Michael Polark – Wolfe Research Operator Greetings and welcome to NeuroPace’s Third Quarter 2024 Earnings Conference Call. At ...

Financial Performance - NeuroPace, Inc. reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of $0.26, and an improvement from a loss of $0.28 per share a year ago, representing an earnings surprise of 26.92% [1] - The company posted revenues of $21.06 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 8.95%, and up from $16.43 million in the same quarter last year [2] - Over the last four quarters, NeuroPace has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - NeuroPace shares have declined approximately 29.4% since the beginning of the year, contrasting with the S&P 500's gain of 25.8% [3] - The current Zacks Rank for NeuroPace is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $20.54 million, and for the current fiscal year, it is -$1.08 on revenues of $77.25 million [7] - The estimate revisions trend for NeuroPace is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - NeuroPace operates within the Medical - Instruments industry, which is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of NeuroPace's stock may be influenced by the overall outlook for the industry [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) Delaware 22-3550230 (State or other jurisdiction of ...

NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Grew revenue 28% year-over-year to $21.1 million in Q3 2024 Increased full-year 2024 revenue guidance to $78 million to $80 million Demonstrated continued operating discipline through further decrease in cash burn Management scheduled to host a conference call today at 4:30 p.m. ET Mountain View, Calif. – November 12, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of ...

NeuroPace, Inc. (NPCE) shares rallied 5.1% in the last trading session to close at $6.35. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.1% loss over the past four weeks. NeuroPace recorded a strong price rise on investors' optimism surrounding its impending third-quarter 2024 financial results, which is slated to be released on Nov. 12, 2024, post the closing bell. The Zacks Consensus Estimate for the th ...